REG - GlaxoSmithKline PLC - Director/PDMR Shareholding

GSKAnnouncement

17/02/2022 14:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220217:nRSQ0448Ca&default-theme=true

RNS Number : 0448C  GlaxoSmithKline PLC  17 February 2022

GlaxoSmithKline plc (the 'Company')

 

Deferred Annual Bonus Plan Awards

On 15 February 2022, the Company granted awards to the Persons Discharging
Managerial Responsibilities ('PDMRs') listed below. The awards have been
granted in accordance with the rules of the GlaxoSmithKline 2017 Deferred
Annual Bonus Plan ('DABP') which was approved by shareholders on 4 May 2017.

Executive Directors are required to defer 50% of any bonus earned into
Ordinary Shares or American Depositary Shares ('ADSs') for a period of three
years. Other members of the GSK Leadership Team are required to defer 25% of
any bonus earned into Ordinary Shares or ADSs for the same period.

The awards have been granted as restricted awards over ADSs for US
participants and as nil-cost options over Ordinary Shares for all other
participants.

The numbers of Ordinary Shares and ADSs shown below are exclusive of dividend
reinvestment that will accrue during the deferral period.

 

 

 

Transaction notification

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Ms E Walmsley
 b)  Position/status                          Chief Executive Officer
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GlaxoSmithKline plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 25 pence each ('Ordinary Shares')

                                              ISIN: GB0009252882
 b)  Nature of the transaction                Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
                                              Deferred Annual Bonus Plan.
 c)  Price(s) and volume(s)                                       Price(s)            Volume(s)
                                                                  £15.712             72,399

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2022-02-15
 f)  Place of the transaction                 N/A

 

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Mr I Mackay
 b)  Position/status                          Chief Financial Officer
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GlaxoSmithKline plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 25 pence each ('Ordinary Shares')

                                              ISIN: GB0009252882
 b)  Nature of the transaction                Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
                                              Deferred Annual Bonus Plan.
 c)  Price(s) and volume(s)                                       Price(s)            Volume(s)
                                                                  £15.712             50,056

                                                                  .

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2022-02-15
 f)  Place of the transaction                 N/A

 

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Dr H Barron
 b)  Position/status                          Chief Scientific Officer and President, R&D
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GlaxoSmithKline plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  American Depositary Shares ('ADSs')

                                              ISIN: US37733W1053
 b)  Nature of the transaction                Deferred Bonus Award of ADSs under the GlaxoSmithKline 2017 Deferred Annual
                                              Bonus Plan.
 c)  Price(s) and volume(s)                                        Price(s)             Volume(s)
                                                                   $42.87               40,617

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2022-02-15
 f)  Place of the transaction                 N/A

 

 

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Mr R Connor
 b)  Position/status                          President, Vaccines and Global Health
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GlaxoSmithKline plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 25 pence each ('Ordinary Shares')

                                              ISIN: GB0009252882
 b)  Nature of the transaction                Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
                                              Deferred Annual Bonus Plan.
 c)  Price(s) and volume(s)                                       Price(s)            Volume(s)
                                                                  £15.712             12,300

                                                                  .

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2022-02-15
 f)  Place of the transaction                 N/A

 

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Ms D Conrad
 b)  Position/status                          Chief People Officer
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GlaxoSmithKline plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 25 pence each ('Ordinary Shares')

                                              ISIN: GB0009252882
 b)  Nature of the transaction                Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
                                              Deferred Annual Bonus Plan.
 c)  Price(s) and volume(s)                                       Price(s)            Volume(s)
                                                                  £15.712             11,370

                                                                  .

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2022-02-15
 f)  Place of the transaction                 N/A

 

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Mr J Ford
 b)  Position/status                          SVP and General Counsel
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GlaxoSmithKline plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 25 pence each ('Ordinary Shares')

                                              ISIN: GB0009252882
 b)  Nature of the transaction                Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
                                              Deferred Annual Bonus Plan.
 c)  Price(s) and volume(s)                                       Price(s)            Volume(s)
                                                                  £15.712             13,998

                                                                  .

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2022-02-15
 f)  Place of the transaction                 N/A

 

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Ms S Jackson
 b)  Position/status                          SVP, Global Communications and CEO Office
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GlaxoSmithKline plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 25 pence each ('Ordinary Shares')

                                              ISIN: GB0009252882
 b)  Nature of the transaction                Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
                                              Deferred Annual Bonus Plan.
 c)  Price(s) and volume(s)                                       Price(s)            Volume(s)
                                                                  £15.712             6,537

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2022-02-15
 f)  Place of the transaction                 N/A

 

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Mr B McNamara
 b)  Position/status                          CEO, GSK Consumer Healthcare
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GlaxoSmithKline plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  American Depositary Shares ('ADSs')

                                              ISIN: US37733W1053
 b)  Nature of the transaction                Deferred Bonus Award of ADSs under the GlaxoSmithKline 2017 Deferred Annual
                                              Bonus Plan.
 c)  Price(s) and volume(s)                                        Price(s)             Volume(s)
                                                                   $42.87               4,306

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2022-02-15
 f)  Place of the transaction                 N/A

 

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Mr L Miels
 b)  Position/status                          Chief Commercial Officer
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GlaxoSmithKline plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 25 pence each ('Ordinary Shares')

                                              ISIN: GB0009252882
 b)  Nature of the transaction                Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
                                              Deferred Annual Bonus Plan.
 c)  Price(s) and volume(s)                                       Price(s)            Volume(s)
                                                                  £15.712             23,796

                                                                  .

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2022-02-15
 f)  Place of the transaction                 N/A

 

 

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Ms S Ramakrishnan
 b)  Position/status                          Chief Digital and Technology Officer
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GlaxoSmithKline plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  American Depositary Shares ('ADSs')

                                              ISIN: US37733W1053
 b)  Nature of the transaction                Deferred Bonus Award of ADSs under the GlaxoSmithKline 2017 Deferred Annual
                                              Bonus Plan.
 c)  Price(s) and volume(s)                                        Price(s)             Volume(s)
                                                                   $42.87               2,482

                                                                   .

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2022-02-15
 f)  Place of the transaction                 N/A

 

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Mr D Redfern
 b)  Position/status                          Chief Strategy Officer
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GlaxoSmithKline plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 25 pence each ('Ordinary Shares')

                                              ISIN: GB0009252882
 b)  Nature of the transaction                Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
                                              Deferred Annual Bonus Plan.
 c)  Price(s) and volume(s)                                       Price(s)            Volume(s)
                                                                  £15.712             15,783

                                                                  .

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2022-02-15
 f)  Place of the transaction                 N/A

 

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Mr R Simard
 b)  Position/status                          President, Pharmaceuticals Supply Chain
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GlaxoSmithKline plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 25 pence each ('Ordinary Shares')

                                              ISIN: GB0009252882
 b)  Nature of the transaction                Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
                                              Deferred Annual Bonus Plan.
 c)  Price(s) and volume(s)                                       Price(s)            Volume(s)
                                                                  £15.712             14,336

                                                                  .

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2022-02-15
 f)  Place of the transaction                 N/A

 

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Mr P Thomson
 b)  Position/status                          President, Global Affairs
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GlaxoSmithKline plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 25 pence each ('Ordinary Shares')

                                              ISIN: GB0009252882
 b)  Nature of the transaction                Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
                                              Deferred Annual Bonus Plan.
 c)  Price(s) and volume(s)                                       Price(s)            Volume(s)
                                                                  £15.712             9,947

                                                                  .

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2022-02-15
 f)  Place of the transaction                 N/A

 

 

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Ms D Waterhouse
 b)  Position/status                          CEO, ViiV Healthcare
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GlaxoSmithKline plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 25 pence each ('Ordinary Shares')

                                              ISIN: GB0009252882
 b)  Nature of the transaction                Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
                                              Deferred Annual Bonus Plan.
 c)  Price(s) and volume(s)                                       Price(s)            Volume(s)
                                                                  £15.712             10,498

                                                                  .

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2022-02-15
 f)  Place of the transaction                 N/A

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHZDLFFLLLFBBD